©Reuters.
NEW YORK – Immunovant, Inc. (NASDAQ:), a clinical-stage immunology company, has been granted a U.S. patent for its second-generation antibody, IMVT-1402, which targets autoimmune diseases. The United States Patent and Trademark Office issued Patent No. No. 11,926,669 with claims including the composition of matter for the binding sequence of IMVT-1402 to the neonatal fragment crystallizable receptor (FcRn), its method of use in the treatment of autoimmune diseases, and methods of manufacturing.
The patent will expire on June 23, 2043, without regard to any extensions to the patent term.
IMVT-1402, developed through HanAll Biopharma’s antibody discovery efforts, showed promise in a Phase 1 clinical trial involving healthy adults. Initial study results indicated a significant reduction in immunoglobulin G (IgG) comparable to batoclimab, another antibody of the same class, but without notable changes in serum albumin and LDL cholesterol levels. Immunovant suggests that weekly administration of IMVT-1402 could maintain consistent reductions in IgG, which could be crucial for sustained efficacy in patients.
The company’s focus is on the advancement of therapies for the treatment of autoimmune diseases, with the aim of improving the quality of life of those affected. However, it is important to note that early clinical trial results may not always be indicative of final results, and further studies are needed to confirm the safety and effectiveness of IMVT-1402.
Immunovant’s progress in developing IMVT-1402 and acquiring the patent represent steps forward in its effort to address the complex needs of people with autoimmune conditions. Nonetheless, the Company recognizes the inherent uncertainties and risks associated with drug development, including the need for additional capital and the challenges of navigating the regulatory landscape.
This news story is based on a press release from Immunovant, Inc. Investors and interested parties are reminded that forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations.
This article was generated with the support of AI and reviewed by an editor. For further information please see our T&Cs.